{"Clinical Trial ID": "NCT01105650", "Intervention": ["INTERVENTION 1:", "Bras 1: CsA", "Fludarabine: administered intravenously, 25 mg/m^2, days -6 to -2 (5 days).", "Cyclophosphamide: administered intravenously, 60 mg/kg, days -5 and -4.", "- Cyclosporin (CsA): administered intravenously, 1.5 mg/kg for a target dose range of 150 to 250 ng/mL per day -3 up to date +14", "Natural killer lymphocytes: administered by infusion for less than one hour; not more than 8.0 x 10^7 cells/kg should be administered.", "Interleukin-2 (IL-2): administered subcutaneously at 9 million units 3 times a week for a total of 6 doses, starting at 4 hours after the infusion of NK cells. (For patients weighing less than 45 kilograms, IL-2 will be administered at 5 million units/m2 3 times a week for 6 doses).", "INTERVENTION 2:", "2nd arm: CsA/methylprednisolone (10mg)/6 Doses of interleukin-2", "Fludarabine: administered intravenously, 25 mg/m^2, days -6 to -2 (5 days).", "Cyclophosphamide: administered intravenously, 60 mg/kg, days -5 and -4.", "- Cyclosporin (CsA): administered intravenously, 1.5 mg/kg for a target dose range of 150 to 250 ng/mL per day -3 up to date +14", "Natural killer lymphocytes: administered by infusion for less than one hour; not more than 8.0 x 10^7 cells/kg should be administered.", "Interleukin-2 (IL-2): administered subcutaneously at 9 million units 3 times a week for a total of 6 doses, starting at 4 hours after the infusion of NK cells. (For patients weighing less than 45 kilograms, IL-2 will be administered at 5 million units/m2 3 times a week for 6 doses).", "Methylprednisolone: administered intravenously, 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9."], "Eligibility": ["Incorporation criteria:", "Diagnosis of recurrent ovarian cancer, Fallopian tube or primary peritoneal cancer that has failed or progressed after at least 2 previous recovery chemotherapys (directed by recurrent/metastatic disease).", "OR", "\u2022 Diagnosis of metastatic breast cancer (female or male) that has progressed or failed on at least one recovery chemotherapy regimen for metastatic diseases and meets the following disease-related criteria:", "If the estrogen receptor or positive progesterone receptor should have progressed in the previous hormonal treatment and/or", "If HER2-neu positive has progressed on trastuzumab, lapatinib or a similar agent", "Women with a history of these two cancers are eligible for this study provided they are currently responding to one of the diseases. Women who have had another disease and have been free of disease for at least 3 years, or have a history of completely resected non-melanoma skin carcinoma or have been successfully treated on site are eligible.", "A specific disease-measurable disease Solid Tumour Assessment Criteria (SISTR) version 1.1 - patients with bones as their only disease site will not be eligible.", "If the history of brain metastases should be stable for at least 3 months after treatment - Brain tomography (CT) will only be required in subjects with known brain metastases at the time of registration or in subjects with clinical signs or symptoms suggesting brain metastases.", "Source of HLA-haploi related cellsIdentical natural killer cell (NK) data (at least by class I serological typing at locus A and B)", "\u2022 Aged 18 or over", "Karnofsky's performance status > or = 50 per cent", "A suitable organ function determined by the following criteria within 14 days of enrolment in the study", "Boneache: platelets > or = 80,000 x 10^9/L and hemoglobin > or = 9 g/dL, not supported by transfusions; absolute neutrophil count (NAC) > or = 1000 x 10^9/L, not supported by growth colony stimulation factor (G-CSF) or granulocyte colony stimulation factor (GM-CSF)", "Renal function: creatinine (Cr) < or = 2.0 mg/dL", "Liver function: Aspartate aminotransferase (AST), Alanine transaminase (ALT), total bilirubin, alkaline phosphatase < 5 times the upper limit of institutional normal (ULN)", "Cardiac: left ventricular ejection fraction > 40% (within 28 days of starting treatment)", "Pulmonary function: > 50% of the diffusion capacity of corrected carbon monoxide (DLCO) and forced expiratory volume in one second (FEV1), if the presence of pleural effusion due to metastatic disease > 40% of corrected LOCD and FEV1 is acceptable (within 28 days of starting treatment)", "\u2022 Capable of being eliminated from prednisone or other immunosuppressive medicinal products for at least 3 days before day 0", "At least 14 days should be between the last previous cancer treatment and the first day of pre-treatment.", "Informed voluntary consent in writing", "- Exclusion criteria:", "Pregnant or breast-feeding - The agents used in this study may be teratogenic to a fetus and there is no information on excretion of agents in breast milk.", "Active infection - subjects must be afabricated, free of antibiotics, and without any radiation damage not studied (infiltrated or lesions with negative cultures or biopsies) are allowed"], "Results": ["Performance measures:", "Response rate", "The response includes the complete response (CR), partial response (PR) and stable disease (SD) as defined by the criteria for assessing response in solid tumours (RECIST v.1.1) for the target lesions assessed by EC or MRI. Complete response (CR), elimination of all target lesions; Partial response (PR), decrease >=30% of the sum of the longest diameter of the target lesions; Stable disease (SD), neither a reduction sufficient to be eligible for PR nor an increase sufficient to be eligible for progressive disease.", "Duration: 3rd month", "Results 1:", "Title of arm/group: Arm 1: CsA", "Description of the arm/group: Fludarabine: administered intravenously, 25 mg/m^2, days -6 to -2 (5 days).", "Cyclophosphamide: administered intravenously, 60 mg/kg, days -5 and -4.", "- Cyclosporin (CsA): administered intravenously, 1.5 mg/kg for a target dose range of 150 to 250 ng/mL per day -3 up to date +14", "Natural killer lymphocytes: administered by infusion for less than one hour; not more than 8.0 x 10^7 cells/kg should be administered.", "Interleukin-2 (IL-2): administered subcutaneously at 9 million units 3 times a week for a total of 6 doses, starting at 4 hours after the infusion of NK cells. (For patients weighing less than 45 kilograms, IL-2 will be administered at 5 million units/m2 3 times a week for 6 doses).", "Total number of participants analysed: 3", "Type of measurement: Number", "Unit of measurement: participants 1", "Results 2:", "Title of arm/group: arms 2: CsA/methylprednisolone (10mg)/6 Doses of interleukin-2", "Description of the arm/group: Fludarabine: administered intravenously, 25 mg/m^2, days -6 to -2 (5 days).", "Cyclophosphamide: administered intravenously, 60 mg/kg, days -5 and -4.", "- Cyclosporin (CsA): administered intravenously, 1.5 mg/kg for a target dose range of 150 to 250 ng/mL per day -3 up to date +14", "Natural killer lymphocytes: administered by infusion for less than one hour; not more than 8.0 x 10^7 cells/kg should be administered.", "Interleukin-2 (IL-2): administered subcutaneously at 9 million units 3 times a week for a total of 6 doses, starting at 4 hours after the infusion of NK cells. (For patients weighing less than 45 kilograms, IL-2 will be administered at 5 million units/m2 3 times a week for 6 doses).", "Methylprednisolone: administered intravenously, 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9.", "Total number of participants analysed: 3", "Type of measurement: Number", "Unit of measurement: participants 2"], "Adverse Events": ["Undesirable Events 1:", "Total: 3/3 (100.00 per cent)", "- Aurial flutter0/3 (0.00 %)", "- Hearing impairment0/3 (0.00 %)", "- Vestibular disorder0/3 (0.00 %)", "- Vision fuzzy0/3 (0.00 %)", "Abdominal pain1/3 (33.33%)", "Death NOS3/3 (100.00%)", "- Fever0/3 (0.00 %)", "Acute renal injury/3 (0.00 %)", "Dyspnoea1/3 (33.33%)", "Inadequate respiratory function//3 (0.00 %)", "Adverse Events 2:", "Total: 3/3 (100.00 per cent)", "- Aurial flutter0/3 (0.00 %)", "Hearing impairment1/3 (33.33%)", "- Vestibular disorder1/3 (33.33%)", "Blurty vision1/3 (33.33%)", "Abdominal pain//3 (0.00 %)", "Death NOS2/3 (66.67 %)", "- Fever0/3 (0.00 %)", "Acute renal injury1/3 (33.33%)", "- Dyspnee0/3 (0.00 %)", "Inadequate respiratory function//3 (0.00 %)"]}